Counting the costs: a nationwide study on healthcare use following an adalimumab biosimilar switch in >1300 inflammatory arthritis patients.

ABSTRACT:

Background

In Denmark, cost savings motivate mandatory biosimilar switches. In 2018, patients switched from originator to biosimilar adalimumab, that is, to GP2017 in Eastern and to SB5 in Western Denmark. However, concerns were raised about additional costs covering, that is, an increased number of outpatient visits due to patient education, treatment monitoring, and patient concerns.

Objectives

To investigate whether the switch led to increased total healthcare costs, defined as costs related to in- and outpatient contacts in hospitals and the primary sector and use of prescription medicine (excluding biological treatment).

Design

Observational cohort study with geographical cluster pseudo-randomization.

Methods

Patients with rheumatoid arthritis, psoriatic a

SUBMITTER: Nabi H 

PROVIDER: S-EPMC11526192 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature